Skip to content

Study · Randomized controlled trial · n = 99 · 2014

7 results

A randomized controlled trial comparing the GLP-1 receptor agonist liraglutide to a sulphonylurea as add on to metformin in patients with established type 2 diabetes during Ramadan: the Treat 4 Ramadan Trial.

Brady EM, Davies MJ, Gray LJ, Saeed MA, Smith D, Hanif W, Khunti K

Diabetes, obesity & metabolism26 Jan 2014Cited by 45 (Europe PMC)

PMID24373063 (opens in a new tab)DOI10.1111/dom.12249 (opens in a new tab)PepBankPUB-24373063
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes fasting during Ramadan, more patients on liraglutide than on sulphonylurea reached the composite endpoint at 12 weeks, but the difference was not statistically significant (OR 4.08, p = 0.06).

    In plain wordsIn adults with type 2 diabetes fasting during Ramadan, more people on liraglutide than sulphonylurea reached the combined target, but not significantly.

    Peptide
    Liraglutide
    Outcome
    No significant changeComposite endpoint (HbA1c <7%, no weight gain, no severe hypoglycaemia) at 12 weeks
    Study

    n = 99

    Comparator
    Sulphonylurea
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Odds ratio
    4.08
    95% CI 0.97, 17.22

    Source sentences

    Summary
    At 12 weeks, more patients in the liraglutide compared with the sulphonylurea group achieved a composite endpoint of haemoglobin A1c (HbA1c) < 7%, no weight gain and no severe hypoglycaemia but this did not reach statistical significance [odds ratio (OR) 4.08, 95% confidence interval (CI) 0.97, 17.22, p = 0.06].
    1 context sentence
    Summary · context
    Ninety-nine adults intending to fast during Ramadan [50% male, mean age 52 years, body mass index (BMI) 32 kg/m(2)] were randomized from two UK sites.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes fasting during Ramadan, HbA1c fell by 0.3% with liraglutide versus no change (+0.02%) with sulphonylurea; the adjusted difference was borderline (p = 0.05, CI -0.83 to 0.01).

    In plain wordsIn adults with type 2 diabetes fasting during Ramadan, HbA1c fell slightly more with liraglutide than with sulphonylurea, but the difference was borderline.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c change at 12 weeks
    Study

    n = 99

    Comparator
    Sulphonylurea
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    HbA1c change
    −0.3%
    liraglutide
    HbA1c change
    0.02%
    sulphonylurea
    Adjusted coefficient
    −0.41
    95% CI -0.83, 0.01

    Source sentences

    Summary
    From a baseline of 7.7% there was no change in HbA1c at 12 weeks in the sulphonylurea (+0.02%) compared with a 0.3% reduction in the liraglutide group (adjusted coefficient -0.41, 95% CI -0.83, 0.01, p = 0.05).
    1 context sentence
    Summary · context
    Ninety-nine adults intending to fast during Ramadan [50% male, mean age 52 years, body mass index (BMI) 32 kg/m(2)] were randomized from two UK sites.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes fasting during Ramadan, weight was significantly reduced with liraglutide compared with sulphonylurea.

    In plain wordsIn adults with type 2 diabetes fasting during Ramadan, liraglutide reduced weight more than sulphonylurea did.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight
    Study

    n = 99

    Comparator
    Sulphonylurea
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Significant reductions were also observed in weight and diastolic blood pressure (BP) in the liraglutide compared with the sulphonylurea group.
    1 context sentence
    Summary · context
    Ninety-nine adults intending to fast during Ramadan [50% male, mean age 52 years, body mass index (BMI) 32 kg/m(2)] were randomized from two UK sites.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes fasting during Ramadan, diastolic blood pressure was significantly reduced with liraglutide compared with sulphonylurea.

    In plain wordsIn adults with type 2 diabetes fasting during Ramadan, liraglutide lowered diastolic blood pressure more than sulphonylurea did.

    Peptide
    Liraglutide
    Outcome
    DecreaseDiastolic blood pressure
    Study

    n = 99

    Comparator
    Sulphonylurea
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Significant reductions were also observed in weight and diastolic blood pressure (BP) in the liraglutide compared with the sulphonylurea group.
    1 context sentence
    Summary · context
    Ninety-nine adults intending to fast during Ramadan [50% male, mean age 52 years, body mass index (BMI) 32 kg/m(2)] were randomized from two UK sites.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes fasting during Ramadan, treatment satisfaction was comparable between liraglutide and sulphonylurea.

    In plain wordsIn adults with type 2 diabetes fasting during Ramadan, people were about equally satisfied with liraglutide and sulphonylurea.

    Peptide
    Liraglutide
    Outcome
    No significant changeTreatment satisfaction
    Study

    n = 99

    Comparator
    Sulphonylurea
    Outcome group
    Patient-reported outcomes · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment satisfaction was comparable across the treatment groups.
    1 context sentence
    Summary · context
    Ninety-nine adults intending to fast during Ramadan [50% male, mean age 52 years, body mass index (BMI) 32 kg/m(2)] were randomized from two UK sites.
  6. 06HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes fasting during Ramadan, there were no episodes of severe hypoglycaemia in either the liraglutide or the sulphonylurea group.

    In plain wordsIn adults with type 2 diabetes fasting during Ramadan, no one in either group had severe low blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeSevere hypoglycaemia
    Study

    n = 99

    Comparator
    Sulphonylurea
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There were no episodes of severe hypoglycaemia in either group
    1 context sentence
    Summary · context
    Ninety-nine adults intending to fast during Ramadan [50% male, mean age 52 years, body mass index (BMI) 32 kg/m(2)] were randomized from two UK sites.
  7. 07HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes fasting during Ramadan, self-recorded episodes of blood glucose at or below 3.9 mmol/l were significantly lower with liraglutide than with sulphonylurea (incidence rate ratio 0.29).

    In plain wordsIn adults with type 2 diabetes fasting during Ramadan, low blood sugar readings were less frequent with liraglutide than with sulphonylurea.

    Peptide
    Liraglutide
    Outcome
    DecreaseSelf-recorded blood glucose episodes at or below 3.9 mmol/l
    Study

    n = 99

    Comparator
    Sulphonylurea
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Incidence rate ratio
    0.29
    95% CI 0.19, 0.41

    Source sentences

    Summary
    self-recorded episodes of blood glucose ≤3.9 mmol/l were significantly lower with liraglutide (incidence rate ratio 0.29, 95% CI 0.19, 0.41, p < 0.0001).
    1 context sentence
    Summary · context
    Ninety-nine adults intending to fast during Ramadan [50% male, mean age 52 years, body mass index (BMI) 32 kg/m(2)] were randomized from two UK sites.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.